Search

Your search keyword '"van Rooij, Luuk C"' showing total 3 results
Start Over Author "van Rooij, Luuk C"
3 results on '"van Rooij, Luuk C"'

1. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT- MS).

Author

Toorop, Alyssa A., van Lierop, Zoë Y. G. J., Gelissen, Liza M. Y., Hoitsma, Elske, Zeinstra, Esther M. P. E., van Rooij, Luuk C., van Munster, Caspar E. P., Vennegoor, Anke, Mostert, Jop P., Wokke, Beatrijs H. A., Kalkers, Nynke F., Hoogervorst, Erwin L. J., van Eijk, Jeroen J. J., Roosendaal, Christiaan M., Kragt, Jolijn J., Eurelings, Marijke, van Genugten, Jessie, Nielsen, Jessica, Sinnige, L. G. F., and Kloosterziel, Mark E.

Subjects
NATALIZUMAB, DRUG monitoring, JOHN Cunningham virus, MULTIPLE sclerosis, DISEASE relapse, PROGRESSIVE multifocal leukoencephalopathy, COVID-19 pandemic
Published
2024
Full Text
View/download PDF

2. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Author

Toorop, Alyssa A, primary, van Lierop, Zoë YGJ, additional, Gelissen, Liza MY, additional, Hoitsma, Elske, additional, Zeinstra, Esther MPE, additional, van Rooij, Luuk C, additional, van Munster, Caspar EP, additional, Vennegoor, Anke, additional, Mostert, Jop P, additional, Wokke, Beatrijs HA, additional, Kalkers, Nynke F, additional, Hoogervorst, Erwin LJ, additional, van Eijk, Jeroen JJ, additional, Roosendaal, Christiaan M, additional, Kragt, Jolijn J, additional, Eurelings, Marijke, additional, van Genugten, Jessie, additional, Nielsen, Jessica, additional, Sinnige, LGF, additional, Kloosterziel, Mark E, additional, Arnoldus, Edo PJ, additional, van Dijk, Gert W, additional, Bouvy, Willem H, additional, Wessels, Mark HJ, additional, Boonkamp, Lynn, additional, Strijbis, Eva MM, additional, van Oosten, Bob W, additional, De Jong, Brigit A, additional, Lissenberg-Witte, Birgit I, additional, Barkhof, Frederik, additional, Moraal, Bastiaan, additional, Teunissen, Charlotte E, additional, Rispens, Theo, additional, Uitdehaag, Bernard MJ, additional, Killestein, Joep, additional, and van Kempen, Zoé LE, additional

Published
2023
Full Text
View/download PDF

3. Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.

Author

Toorop, Alyssa A, Wessels, Mark HJ, Boonkamp, Lynn, Gelissen, Liza MY, Hoitsma, E, Zeinstra, Esther MPE, van Rooij, Luuk C, van Munster, Caspar EP, Vennegoor, Anke, Mostert, Jop P, Wokke, Beatrijs HA, Kalkers, Nynke F, Hoogervorst, Erwin LJ, van Eijk, Jeroen JJ, Roosendaal, Christiaan M, Kragt, Jolijn J, Eurelings, Marijke, van Genugten, Jessie, Nielsen, Jessica, and Sinnige, LGF

Abstract

Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs).We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab.We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS.A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence.Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results